Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 228

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1

Open access
Lee, Joo Sang, Ruppin, Eytan·2019·JAMA Oncology

Abstract

IMPORTANCE: Therapies to inhibit programmed cell death 1 and its ligand (anti-PD-1/PD-L1) provide significant survival benefits in many cancers, but the efficacy of these treatments varies considerably across different cancer types. Identifying the underlying variables associated with this cancer type-specific response remains an important open research challenge. OBJECTIVE: To evaluate systematically a multitude of neoantigen-, checkpoint-, and immune response-related variables to determine the key variables that accurately predict the response to anti-PD-1/PD-L1 therapy across different cancer types. DESIGN, SETTING, AND PARTICIPANTS: This analysis of a broad range of data used whole-exome and RNA sequencing of 7187 patients from the publicly available Cancer Genome Atlas and the objective response rate (ORR) data of 21 cancer types obtained from a collection of clinical trials. Thirty-six variables of 3 distinct classes considered were associated with (1) tumor neoantigens, (2) tumor microenvironment and inflammation, and (3) the checkpoint targets. The performance of each class of variables and their combinations in predicting the ORR to anti-PD-1/PD-L1 therapy was evaluated. Accuracy of predictions was quantified with Spearman correlation measured using a standard leave-one-out cross-validation, a statistical method of evaluating a statistical model by dividing data into 2 segments: one to train the model and the other to validate the model. Data were collected from October 19 through 31, 2018, and were analyzed from November 1 through December 14, 2018. MAIN OUTCOMES AND MEASURES: Response to anti-PD-1/PD-1 therapy. RESULTS: Among the 36 variables, estimated CD8+ T-cell abundance was the most predictive of the response to anti-PD-1/PD-L1 therapy across cancer types (Spearman R = 0.72; P < 2.3 × 10-4), followed by the tumor mutational burden (Spearman R = 0.68; P < 6.2 × 10-4), and the fraction of samples with high PD1 gene expression (Spearman R = 0.68; P < 6.9 × 10-4). Notably these top 3 variables cover the 3 classes considered, and their combination is highly correlated with response (Spearman R = 0.90; P < 4.1 × 10-8), explaining more than 80% of the ORR variance observed across different tumor types. CONCLUSIONS AND RELEVANCE: That we know of, this is the first systematic evaluation of the different variables associated with anti-PD-1/PD-L1 therapy response across different tumor types. The findings suggest that the 3 key variables can explain most of the observed cross-cancer response variability, but their relative explanatory roles may vary in specific cancer types.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2019.2311

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 5

  1. Miao, 2016, Genomic determinants of cancer immunotherapy., Curr Opin Immunol, 41, 32, 10.1016/j.coi.2016.05.010 · DOI
  2. Chow, 2016, Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 Expansion Cohort., J Clin Oncol, 34, 3838, 10.1200/JCO.2016.68.1478 · DOI · Paper page
  3. Paré, 2018, Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types., Ann Oncol, 29, 2121, 10.1093/annonc/mdy335 · DOI
  4. Harms, 2015, The distinctive mutational spectra of polyomavirus-negative Merkel cell carcinoma., Cancer Res, 75, 3720, 10.1158/0008-5472.CAN-15-0702 · DOI · Paper page
  5. George, 2015, Comprehensive genomic profiles of small cell lung cancer., Nature, 524, 47, 10.1038/nature14664 · DOI · Paper page

Cited by

See all 228

Metadata

Authors
Lee, J. S., & Ruppin, E.
Venue
JAMA Oncology
Published
2019-11-01
Volume
5
Issue
11
Pages
1614
ISSN
2374-2437 (ISSN-L)
OpenAlex
W2969643975
Cited by
228
References
9
FWCI
11.70
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1. https://app.cochat.ai/papers/10.1001/jamaoncol.2019.2311
The paper
Lee, J. S., & Ruppin, E. (2019). Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2019.2311

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.